• 55 Commercial Road, Medical Oncology, South Block

    3004 Melbourne

    Australia

Accepting PhD Students

20022021

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Scope: translational immuno-oncology, including:

  • understanding how oncogenic signaling interfaces with anti-cancer immune responses
  • studying the tumour-immune microenvironment as a complex ecosystem, employing multi-omic and spatial techniques to understand the interplay between structure and function in tumour masses
  • mechanisms and biomarkers of immune-related adverse events

Setting: melanoma, thoracic tumours, head and neck cancer, and the application of cancer immunotherapy across cancer types.

Strategy: leverage integrative immune and genomic analyses to identify how complex micro-environmental features and distinct cellular compartments interact to influence tumour growth, treatment outcomes, and treatment-related toxicity.

Clinical activities

Core subspecialty areas in Medical Oncology:

  • Melanoma (all subtypes)
  • Head and neck cancers
  • Lung cancer
  • Immunotherapy-related toxicity

Education/Academic qualification

PhD, University of Melbourne

Fellowship of the Royal Australasian College of Physicians (FRACP)

External positions

Medical Oncologist, Alfred Hospital

Research area keywords

  • Cancer Immunology
  • Immunotherapy
  • Targeted Therapy
  • Melanoma
  • Lung Cancer
  • Genomics
  • Bioinformatics
  • Oncology
  • Immune-related toxicity
  • Microbiome

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma

Mitra, A., Andrews, M. C., Roh, W., De Macedo, M. P., Hudgens, C. W., Carapeto, F., Singh, S., Reuben, A., Wang, F., Mao, X., Song, X., Wani, K., Tippen, S., Ng, K. S., Schalck, A., Sakellariou-Thompson, D. A., Chen, E., Reddy, S. M., Spencer, C. N., Wiesnoski, D. & 17 others, Little, L. D., Gumbs, C., Cooper, Z. A., Burton, E. M., Hwu, P., Davies, M. A., Zhang, J., Bernatchez, C., Navin, N., Sharma, P., Allison, J. P., Wargo, J. A., Yee, C., Tetzlaff, M. T., Hwu, W. J., Lazar, A. J. & Futreal, P. A., 2020, In : Nature Communications. 11, 1, 18 p., 1839.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

Galvani, E., Mundra, P. A., Valpione, S., Garcia-Martinez, P., Smith, M., Greenall, J., Thakur, R., Helmink, B., Andrews, M. C., Boon, L., Chester, C., Gremel, G., Hogan, K., Mandal, A., Zeng, K., Banyard, A., Ashton, G., Cook, M., Lorigan, P., Wargo, J. A. & 2 others, Dhomen, N. & Marais, R., 12 Feb 2020, In : Nature Communications. 11, 1, 9 p., 853.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases

Arulananda, S., Parakh, S., Palmer, J., Goodwin, M., Andrews, M. C. & Cebon, J. S., Aug 2019, In : Cancer Reports. 2, 4, 6 p., e1183.

Research output: Contribution to journalArticleResearchpeer-review

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Wei, S. C., Anang, N. A. A. S., Sharma, R., Andrews, M. C., Reuben, A., Levine, J. H., Cogdill, A. P., Mancuso, J. J., Wargo, J. A., Pe’er, D. & Allison, J. P., 5 Nov 2019, In : Proceedings of the National Academy of Sciences of the United States of America. 116, 45, p. 22699-22709 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
10 Citations (Scopus)

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Amaria, R. N., Menzies, A. M., Burton, E. M., Scolyer, R. A., Tetzlaff, M. T., Antdbacka, R., Ariyan, C., Bassett, R., Carter, B., Daud, A., Faries, M., Fecher, L. A., Flaherty, K. T., Gershenwald, J. E., Hamid, O., Hong, A., Kirkwood, J. M., Lo, S., Margolin, K., Messina, J. & 20 others, Postow, M. A., Rizos, H., Ross, M. I., Rozeman, E. A., Saw, R. P. M., Sondak, V., Sullivan, R. J., Taube, J. M., Thompson, J. F., van de Wiel, B. A., Eggermont, A. M., Davies, M. A., The International Neoadjuvant Melanoma Consortium members, Ascierto, P. A., Spillane, A. J., van Akkooi, A. C. J., Wargo, J. A., Blank, C. U., Tawbi, H. A. & Long, G. V., Jul 2019, In : The Lancet Oncology. 20, 7, p. e378-e389 12 p.

Research output: Contribution to journalReview ArticleOtherpeer-review

17 Citations (Scopus)